![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 39, 27339-27342, September 24, 1999
B Kinase (IKK) and NF-
B
Activation*
From the Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California, San Diego, La Jolla, California 92093-0636
NF- Initially, NF- Potent NF- Polyubiquitination involves a cascade of enzymatic reactions, the
first of which is ATP-dependent and catalyzed by E1
ubiquitin-activating enzyme to form an E1-ubiquitin thioester. The
second reaction is catalyzed by the E2 ubiquitin-conjugating enzymes,
which receive activated ubiquitin from E1. The last step in the
cascade, the transfer of activated ubiquitin from the E2-ubiquitin
intermediate to the substrate, is catalyzed by a third group of
enzymes, the E3 ubiquitin-protein ligases (15). The E3 group is very
heterogeneous, and most of its members are poorly characterized.
Recently, a cell-free system that catalyzes the ubiquitination of
N-terminally phosphorylated I E3RSI The enzymes that catalyze the ubiquitination of
phospho-I Once it became clear that the key step in NF- IKK IKK
![]()
INTRODUCTION
TOP
INTRODUCTION
Regulation of I
kB Turnover
I
B Kinase and Its...
IKK Function
REFERENCES
B/Rel proteins are dimeric,
sequence-specific transcription factors that control a variety of
important biological decisions from formation of dorsal-ventral
polarity in insects to activation of inflammatory and innate immune
responses (reviewed in Ref. 1). NF-
B proteins are related through
the Rel homology domain (RHD),1 which subjects them
to a particular type of regulation, centered around nuclear-cytoplasmic
shuttling (reviewed in Ref. 2). The RHD serves several functions. It is
the dimerization and DNA binding domain, and we have learned in atomic
detail how RHDs dimerize and interact with DNA (3). In addition, the
RHD contains a nuclear localization sequence (NLS), and most
importantly it is the site for binding of inhibitors of NF-
B, the
I
Bs (reviewed in Ref. 2). The I
Bs also form a small family with a
core composed of six or more ankyrin repeats, an N-terminal regulatory
domain, and a C-terminal domain that contains a PEST motif (reviewed in Ref. 2). By binding to NF-
B dimers, the I
Bs mask their NLS and
cause their cytoplasmic retention. Some I
Bs, such as I
B
, contain a nuclear export sequence and when combining with NF-
B dimers in the nucleus (which the I
Bs can presumably enter by diffusion) cause their exportin-mediated transport to the cytoplasm (4). Recently the three-dimensional structures of NF-
B·I
B ternary complexes (composed of the RHDs of p50 and p65 and the ankyrin
repeat core of I
B
) were solved (5, 6). These fascinating structures indicate that the ankyrin repeats of I
B
form a
slightly bent cylinder through a stacked arrangement of
-helices
that compose their ankyrin repeats. The peptide loops that connect these helices make specific contacts with the two RHDs, whose N-terminal Ig-like repeats flank the I
B core; the C-terminal Ig-like
repeats (responsible for dimerization) contact each other with the
I
B cylinder lying on top of them. Although the structures solved by
two independent groups differ on the way by which I
B masks the NLS
located next to the C-terminal Ig-like repeats of the RHDs (5, 6) it is
likely that the first two ankyrin repeats sterically hinder the binding
of importins to the NLS of NF-
B.
![]()
Regulation of I
kB Turnover
TOP
INTRODUCTION
Regulation of I
kB Turnover
I
B Kinase and Its...
IKK Function
REFERENCES
B was thought to be a B cell-specific
transcription factor (1). However, it was quickly recognized that NF-
B activity can be induced in most cell types upon treatment with
phorbol esters, the proinflammatory cytokines, tumor necrosis factor
(TNF), and interleukin 1 (IL-1) and bacterial endotoxin. Subsequently,
the list of NF-
B inducers has grown to contain double-stranded (ds)
RNA, viruses, and the Tax protein of HTLV-1. It was also recognized
that upon cell stimulation with these inducers, NF-
B dimers
translocate from the cytoplasm to the nucleus where they bind target
genes and regulate their transcription. Subsequently, the nuclear
translocation of NF-
B was found to parallel and depend on induced
degradation of I
Bs (reviewed in Refs. 2 and 7).
B activators can induce almost complete degradation of
I
Bs (especially I
B
) within minutes. This process, which is
mediated by the 26 S proteasome (8, 9), depends on phosphorylation of
two conserved serines (Ser-32 and Ser-36 in I
B
) in the N-terminal regulatory domain of I
B (10-12). Homologous serines are also
required for degradation of the Drosophila I
B homolog,
Cactus (13). Even the substitution of a single serine can considerably
inhibit I
B degradation. Furthermore, these serines cannot be
replaced by threonine, indicating that the kinase that
phosphorylates them is serine-specific (12). In the presence of
proteasome inhibitors, N-terminally phosphorylated I
B
accumulates very rapidly, indicating that its phosphorylation precedes
its degradation and does not result in dissociation from NF-
B (8,
9). Phosphorylated I
Bs undergo without delay a second
post-translational modification, polyubiquitination. The major acceptor
sites for ubiquitin in I
B
are arginines 21 and 22, whose
substitution with lysines considerably retards its degradation (12,
14).
B
was established and used to show
that the only regulated step in the I
B degradation pathway is the
phosphorylation reaction (16). By contrast, the ubiquitinating activity
that specifically recognizes phosphorylated I
B is constitutive. Most importantly, Yaron et al. (17) have elegantly employed this cell-free system and cutting edge protein purification and sequence determination technology to molecularly identify the recognition component of the phospho-I
B-specific E3 activity. This protein, named E3RSI
B, is a member of the F-box/WD-repeat family
(reviewed in Ref. 18). Interestingly, other members of this family,
which contain an F-box and one or two WD or leucine-rich repeats, are
essential components of E3 activities involved in regulated protein
degradation (19-21). In the case of E3RSI
B, Cdc4, and
Grr1, recognition of the phosphoamino acid embedded within a specific
sequence is believed to be mediated by the WD repeats (17, 18). The F
box, on the other hand, is responsible for binding to Skp1, which in
turn binds to members of the Cullin family, such as Cdc53 (20, 21). The
Cullin subunit of the E3 complex appears to be responsible for
recruitment of E2-ubiquitin onto the phosphorylated substrate (18).
B is identical to
-TrCP, which was previously
isolated via a two-hybrid screen as a protein that binds to the
phosphorylated version of the HIV protein Vpu (22). Phospho-Vpu binds
CD4, a T cell membrane protein, to induce its ubiquitination and
degradation. Curiously, Vpu contains a sequence very similar to the one
surrounding the phosphoacceptor sites of I
Bs
(Fig. 1). The same sequence is also
present in
-catenin, another protein whose abundance is regulated
via a ubiquitin-dependent degradation pathway (23). Furthermore, genetic analysis has shown that degradation of the Drosophila
-catenin homolog Armadillo depends on a
homolog of E3RSI
B called Slimb (24). Thus, rather than
serving as a recognition sequence for the I
B kinase, the conserved
sequence surrounding the I
B N-terminal phosphoacceptor sites is a
recognition site for E3RSI
B, whose binding to I
B is
strictly dependent on phosphorylation of these sites (17). Indeed, the
sequence similarity between the I
B and
-catenin phosphorylation
sites led other investigators to examine and confirm the involvement of
-TrCP in I
B ubiquitination and degradation (25).
Coimmunoprecipitation experiments show that like other F box proteins,
E3RSI
B also associates with Skp1 and Cul1 (25). However,
it remains to be established whether Cul1 rather than other Cullins is
a physiological component of the E3I
B complex. In
addition, the particular E2 that works in conjunction with
E3I
B in vivo needs to be identified.

View larger version (18K):
[in a new window]
Fig. 1.
Alignment of phosphorylation sites that
dictate the ubiquitin-dependent degradation of
I
B proteins,
-catenin
and Vpu (it is actually CD4 to which Vpu binds that is being
degraded). The consensus sequence for recognition by
E3RSI
B/
-TrCP is indicated. SP,
phosphoserine;
, hydrophobic amino acid; X, any amino
acid.
![]()
I
B Kinase and Its Regulation
TOP
INTRODUCTION
Regulation of I
kB Turnover
I
B Kinase and Its...
IKK Function
REFERENCES
B are constitutively active. Therefore the regulated step
that dictates the fate of I
B is in most cases phosphorylation of the
two N-terminal serines. As the E3I
B complex may also be
involved in degradation of CD4 and
-catenin, the phosphorylation
step is also the one responsible for specificity in this pathway. There
are only two exceptions to this universal pathway for NF-
B
activation. The first is activation of NF-
B in response to UV
radiation, which although dependent on I
B degradation does not
involve I
B phosphorylation at the N-terminal sites (26, 27). The
second exception is anoxia, which stimulates phosphorylation of
I
B
at tyrosine 42 (28). The tyrosine-phosphorylated I
B
was
suggested to bind to the SH2 domain of phosphatidylinositol 3-kinase,
which yanks it away from NF-
B (29). Tyrosine 42, however, is not
conserved in other I
Bs, and therefore the universality of this
pathway is questionable. The control of I
B phosphorylation in
response to all other NF-
B activating stimuli rests on the shoulders
of the I
B kinase (IKK) complex.
B activation was I
B
phosphorylation, a search for a stimulus-responsive protein kinase
catalyzing this event was initiated. This effort bore fruit when a
protein kinase activity that is specific for the N-terminal regulatory
serines of I
Bs was identified (30, 31). This activity, named IKK, is
serine-specific and responsive to a number of potent NF-
B
activators, most notably TNF and IL-1, which stimulate its activity
with kinetics that match those of I
B
degradation (30). Furthermore, the extent to which IKK is activated seems to dictate the
kinetics of I
B degradation. Gel filtration experiments suggest that
IKK is a protein complex, and indeed protein purification, microsequencing, and molecular cloning resulted in identification of
three IKK polypeptides. Two of these polypeptides, IKK
(IKK1) and
IKK
(IKK1), are catalytic subunits (30-33), whereas the third polypeptide, IKK
(also known as NEMO), is regulatory (34, 35).
was also isolated through a two-hybrid screen as a protein
that interacts with the mitogen-activated protein kinase kinase kinase
(MAP3K), NIK (36). Although in overexpression experiments NIK acts as a
potent IKK and NF-
B activator (36-39), recent experiments question
its involvement in IKK activation by either TNF or IL-1 (40).
Furthermore, interaction between NIK and IKK
occurs upon overexpression of the two in mammalian cells but was not detected under
physiological conditions. In addition, the IKK
subunit, which was
proposed to be the preferential target for NIK (41), is not directly
involved in IKK activation (42).
and IKK
have very similar primary structures (52% overall
identity) with protein kinase domains at their N terminus, a leucine
zipper (LZ), and a helix-loop-helix (HLH) motif at their C-terminal
portion (Fig. 2). IKK
/NEMO does not
contain a recognizable catalytic domain but is composed mostly of three
large
-helical regions, including a LZ (Fig. 2). Biochemical
analysis indicates that the predominant form of IKK is an IKK·IKK
heterodimer associated with either a dimer or trimer of IKK
(34). An
IKK complex-associated protein (IKAP) has also been described and
proposed to be involved in IKK activation (43) but is not a readily
detected constituent of the IKK complex; therefore its physiological
significance and function are not clear.

View larger version (12K):
[in a new window]
Fig. 2.
The three components of IKK. The major
structural and functional motifs of IKK
, IKK
, and IKK
are
indicated. KD, kinase domain. The open boxes in
IKK
indicate
-helical regions within them, the hatched
boxes denote coiled coil and leucine zipper (LZ)
motifs.
Native IKK complexes purified from mammalian cells seem to be
assembled from IKK
·IKK
heterodimers plus an undetermined number of IKK
subunits (34). Yet, cross-linking experiments indicate that
in vitro IKK
and IKK
can form both homo- and
heterodimers in a manner that depends on integrity of their LZ motifs
(33). When examined as transiently expressed proteins in mammalian
cells, IKK
and IKK
exhibit identical activation kinetics and
substrate specificities (31, 32). Although highly reproducible, such experiments are misleading because the transiently expressed proteins readily interchange with their endogenous counterparts and thus are
incorporated into IKK complexes (32). Thus when epitope-tagged IKK
is precipitated and its associated I
B kinase activity is measured it
is not clear whether one measures its activity or those of endogenous
IKK
or IKK
with which it associates. Indeed, transiently
expressed catalytically inactive IKK
and IKK
associate with a
substantial amount of cytokine-inducible I
B kinase activity (32).
Nevertheless, overexpression of catalytically inactive IKK
or IKK
inhibits NF-
B activation in response to TNF, measured by
translocation of p65/RelA to the nucleus (32).
The kinase activities of IKK
and IKK
or their abilities to be
activated depend on LZ-mediated dimerization, and LZ mutations that
interfere with this process abolish kinase activity (32, 33). IKK
or
IKK
activity is also abolished by mutations within the HLH motif
(32, 33). These mutations, however, do not interfere with dimerization
or binding to IKK
. Rather, the HLH motif interacts with the kinase
domain and can stimulate its activity when expressed in trans (42). IKK
activation also requires an intact IKK
subunit. No IKK or NF-
B
activity can be elicited in IKK
/NEMO-deficient cells that are
treated with TNF, IL-1, endotoxin, or dsRNA (35). In addition, IKK
complexes assembled on a mutant of IKK
that lacks its C-terminal LZ
are refractory to all of these agonists (34). These results provide a
genetic proof for the importance of IKK in NF-
B activation and
suggest that the C-terminal region of IKK
is necessary for
recruitment of upstream activators.
Activation of IKK depends on phosphorylation of its IKK
subunit
(42). The first evidence for the role of phosphorylation was obtained
by treatment of purified, activated IKK complex with protein
phosphatase 2A, which resulted in its inactivation (30). Furthermore,
treatment of cells with protein phosphatase 2A inhibitor results
in activation of IKK (and NF-
B). More recently, incubation of cells
with TNF was shown to stimulate the phosphorylation of all three IKK
subunits (42). IKK
and IKK
are phosphorylated exclusively at
serines. The location of these serines was biochemically mapped for
IKK
, and by conjecture it can be assumed that equivalent sites are
phosphorylated on IKK
. Two of the IKK
phosphoacceptors are
located in its activation loop (42), a portion of the kinase domain
that is involved in phosphorylation-dependent activation of
other protein kinases (44). The non-phosphorylated form of the
activation loop folds back onto the kinase domain and interferes with
entry of ATP and peptide substrates into the catalytic pocket. Phosphorylation moves the activation loop away from the catalytic pocket, thus allowing its interaction with substrates (45). Replacement
of the two phosphoacceptor serines (Ser-177 and Ser-181) of IKK
with
alanines prevents activation, whereas their replacement with
phosphomimetic glutamate residues results in constitutive activation
(31, 42). Interestingly, however, replacement of the two equivalent
serines (Ser-176 and Ser-180) in IKK
abolishes autophosphorylation
of this subunit but has no effect on stimulation of total IKK activity
by TNF, IL-1, or the upstream kinases MEKK1 and NIK (42). These
results, which underscore the biochemical differences between the two
catalytic subunits, strongly suggest that IKK is activated as a result
of IKK
phosphorylation and that IKK
phosphorylation, although
concurrent with that of IKK
, is not essential for stimulation of
I
B kinase activity. In other words, the IKK
subunit and not
IKK
serves as the target for upstream activators involved in
proinflammatory signaling that are recruited to the complex via
IKK
.
Phosphorylation is also involved in negative regulation of IKK
activity. In addition to the activation loop, IKK
is extensively phosphorylated at its C-terminal region, which contains multiple serines (42). Phosphorylation of these sites depends on autokinase activity. Mutagenesis experiments indicate that the C-terminal autophosphorylation sites are involved in shutoff of kinase activity (42). Replacement of 9 or 10 of the C-terminal serines with alanines
results in a mutant whose activation lasts four times longer than that
of the wild-type enzyme, whereas substitution of the same sites with
phosphomimetic glutamic acid residues results in a mutant enzyme that
can hardly be activated. Based on these results, a three-state model
was proposed to explain the regulation of IKK activity
(42). Initially, the inactive IKK complex
is not phosphorylated on its catalytic subunits. In response to
upstream stimuli, IKK-Ks are activated and recruited to the complex via IKK
. This results in phosphorylation of IKK
and activation of IKK. We presume that initially only a small fraction of IKK is activated through direct phosphorylation by IKK-Ks. However, through intramolecular trans-autophosphorylation the activated IKK
subunit can phosphorylate the adjacent subunit, which can be either IKK
or
IKK
(in the case of a homodimer), as well as other inactive IKK
complexes through an intermolecular reaction. Indeed, the mere
overexpression of IKK
in Sf9 cells is sufficient for its activation, which depends on autophosphorylation at the activation loop. The activated IKK complexes phosphorylate the I
B subunits of
NF-
B·I
B complexes, triggering their
ubiquitin-dependent degradation and activation of NF-
B.
Concurrently, the activated IKK
subunits (and presumably the IKK
subunits as well) undergo C-terminal autophosphorylation. This
reaction, which is unlikely to be processive, operates as a timing
device such that when at least nine of the C-terminal serines are
phosphorylated the enzyme reaches a low activity state. This
facilitates inactivation of IKK by phosphatases once the upstream
signal has disappeared. As the C-terminal autophosphorylation sites are
adjacent to the HLH motif they may exert their negative effect on
kinase activity by changing the conformation of this intrinsic
activator domain and affecting its interaction with the kinase domain.
This mode of regulation explains why IKK is usually activated in a
highly transient fashion. Because of the ability of IKK
to propagate
its active state via autophosphorylation at the activation loop it is
important to have an active way to reduce kinase activity and render it
sensitive to inactivation by a phosphatase. Without this prolonged IKK
activation would result in prolonged NF-
B activation followed by
increased production of both primary and secondary inflammatory
mediators. As these mediators can lead to further NF-
B activation
(46), there is a genuine risk that in the absence of an efficient way
to rapidly terminate both IKK and NF-
B activities even a minor
proinflammatory insult would result in a major catastrophe, such as
septic shock. Interestingly, constitutive IKK activation was recently
detected in Hodgkin's disease cells (47). This results in constitutive NF-
B activation, which protects these cells from induction of apoptosis by radio- and chemotherapy (48). In fact, elevated NF-
B
and IKK activity may protect numerous types of tumors from apoptosis-inducing therapies (49). Thus, IKK offers a reasonable target
for development of new anti-tumor drugs.
|
| |
IKK Function |
|---|
kB Turnover
B Kinase and Its...
|
|---|
The presence of two closely related, yet distinct catalytic
subunits within the IKK complex is a curiosity that raises a few questions and possibilities. Are IKK
and IKK
completely redundant and thus have identical functions? Alternatively, each subunit may be
responsible for phosphorylation of different substrates and may even be
subject to differential regulation. Initially, little differences
between IKK
and IKK
were observed, and it was assumed that the
two have identical function. Yet more recent experiments, discussed
above, suggested that IKK
and not IKK
is involved in IKK
activation by proinflammatory stimuli (42). It therefore became
important to use a genetic approach to examine the relative functions
of IKK
and IKK
. This was done through the use of gene targeting
technology to generate mouse strains deficient in either catalytic subunit.
The first surprising result produced by these experiments was the
phenotype of IKK
-deficient mice. The complete loss of IKK
results
in perinatal lethality. IKK
/
mice are
born alive but die within 30 min (50). Newborn
IKK
/
mice display rudimentary limbs and
tail, a large omphalocele, and severe craniofacial deformity, but most
striking is their skin, which is taut, shiny, and completely devoid of
wrinkles. Histopathological examination reveals that the mutant mice
contain limb bones of almost normal size, but they are hidden under
their thickened skin (50). The major problem with the limb bones is syndactyly and absence of phalanges, whereas more proximal elements appear normal. Other notable skeletal abnormalities include a partially
split sternum, fused vertebrae, and severe truncation of the skull.
Yet, the most dramatic change is in the structure of the
epidermis; the mutant epidermis is up to 10-fold thicker than normal,
whereas the dermis appears unaltered. Increased thickness of the mutant
epidermis is due to hyperproliferation of cells at the basal layer
(which is normally one cell thick). In addition, there appears to be a
block to keratinocyte differentiation such that instead of having a
stratified epidermis the mutant mice are covered by a uniform layer of
cells. The mutant epidermis lacks the upper layer of keratinized cells
resulting in increased adhesiveness and stickiness. Transverse sections
reveal that mutant limbs and tail are actually "glued" back to the
body (50). As epidermal thickenings, such as the apical ectodermal
ridge, are an important source for morphogens that control skeletal
development many of the morphogenetic defects in
IKK
/
mice could be secondary to a primary
defect in epidermal differentiation.
The second surprise was that IKK
is not required for IKK activation
by proinflammatory stimuli. Upon stimulation of IKK
/
embryonic fibroblasts, primary keratinocytes, or liver tissue with
IL-1, TNF, or endotoxin, normal IKK activation and I
B
degradation were observed (50). Despite normal induction of IKK activity and I
B
degradation, IKK
/
fibroblasts exhibit an
approximately 50% decrease in total NF-
B DNA binding activity. Thus
although IKK
does not play a primary role in IKK activation, it may
still be involved in stimulating the translocation of NF-
B to the
nucleus or enhancing its DNA binding activity. Regardless of the
partial defect in NF-
B activation, the IKK complex in
IKK
/
cells is of normal size and exhibits
normal regulation. As none of the currently available knockout mouse
mutants that are deficient in any of the known NF-
B subunits or
components of the IL-1 and TNF signaling pathways exhibit a similar
phenotype, it is unlikely that the developmental and morphogenetic
defects in IKK
/
animals are caused by
alterations in NF-
B activation. Most likely, IKK
regulates the
activity of a key determinant of keratinocyte proliferation and
differentiation. It is the altered regulation of this putative IKK
substrate that leads to the morphogenetic defects in
IKK
/
mice.
By contrast to IKK
, the IKK
subunit fulfills all expectations.
Although its loss also results in embryonic lethality, the phenotype of
IKK
/
embryos is completely different from
that of IKK
/
embryos at the same
developmental stage. IKK
/
embryos die
approximately at embryonic day (E) 12.5, and histopathological examination reveals that the cause of death is massive liver apoptosis (51, 52). By comparison, IKK
/
embryos or
neonates have a perfectly normal liver. The massive increase in
apoptosis of hepatocytes in IKK
/
embryos
is strikingly similar to the major pathology observed in
RelA
/
embryos, which die at E14.5 because of
liver degeneration (53). Because mice that are deficient in both p65
(RelA) and p50 (NF
B1) also die at E12.5 (54), it appears that the
loss of IKK
results in a more severe decrease in NF-
B activity
than the loss of p65 (RelA) alone. RelA expression is needed to protect
cells from TNF-induced apoptosis (55-58). Indeed, mice that lack both
RelA and TNF are viable and have normally appearing liver (59). Thus the liver degeneration in RelA
/
mice is due
to increased TNF-induced hepatocyte apoptosis unopposed by NF-
B, and
most likely this is the cause of death in
IKK
/
embryos. Correspondingly,
IKK
-deficient cells are unable to activate IKK or NF-
B in
response to either TNF or IL-1 (51, 52). Thus, unlike IKK
, IKK
is
absolutely required for activation of IKK and phosphorylation of
I
Bs.
Although these experiments provide rather definitive evidence for the
different and non-overlapping functions of IKK
and IKK
they
generate a new dilemma. Does IKK
exert its morphogenetic function as
a component of the "classical" IKK complex composed of IKK
,
IKK
, and IKK
, or does it also function as a stand-alone kinase or
a component of a completely different complex (Fig. 3)? An answer to this difficult question
will require extensive biochemical analysis of IKK complexes in
keratinocytes, the cell type in which IKK
exhibits its unique
function. Once the biochemical form of IKK
involved in keratinocyte
differentiation is identified, it will be possible to determine how its
activity is regulated and which of its substrates plays a
fate-determining role in these cells. Despite the many remaining
questions, it is satisfying to witness the rapid progress in
understanding IKK function and regulation, given the rather recent
discovery of this important protein kinase.
| |
ACKNOWLEDGEMENTS |
|---|
I thank B. Thompson for excellent manuscript assistance and M. Delhase, Y. Hu, and D. Rothwarf for artwork.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 1999 Minireview Compendium, which will be available in December, 1999. Work in the author's laboratory is supported by the National Institutes of Health (NIEHS and NIAID) and the Department of Energy.
A Frank and Else Schilling American Cancer Society Research
Professor. To whom correspondence should be addressed: Laboratory of
Gene Regulation and Signal Transduction, Dept. of Pharmacology, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA
92093-0636. Tel.: 619-534-1361; Fax: 619-534-8158; E-mail: karinoffice@ucsd.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
RHD, Rel homology
domain;
NLS, nuclear localization sequence;
TNF, tumor necrosis factor;
IL, interleukin;
IKK, I
B kinase;
LZ, leucine zipper;
HLH, helix-loop-helix;
IKAP, IKK complex-associated protein;
IKK-K, IKK
kinase.
| |
REFERENCES |
|---|
kB Turnover
B Kinase and Its...
|
|---|
| 1. | Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Baldwin, A. S. (1996) Annu. Rev. Immunol. 14, 649-681[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Chen, F. E., Huang, D-B., Chen, Y.-Q., and Ghosh, G. (1998) Nature 391, 410-413[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R. T., Virelizier, J. L., and Dargemont, C. (1997) J. Cell Sci. 110, 369-378[Abstract] |
| 5. | Huxford, T., Huang, D. B., Malek, S., and Ghosh, G. (1998) Cell 95, 759-770[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Jacobs, M. D., and Harrison, S. C. (1998) Cell 95, 749-758[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Verma, I. M.,
Stevenson, J. K.,
Schwarz, E. M.,
Van Antwerp, D.,
and Miyamoto, S.
(1995)
Genes Dev.
9,
2723-2735 |
| 8. | Alkalay, I., Yaron, A., Hatzubai, A., Jung, S., Avraham, A., Gerlitz, O., Pashut-Lavon, I., and Ben-Neriah, Y. (1995) Mol. Cell. Biol. 15, 1294-1301[Abstract] |
| 9. | DiDonato, J. A., Mercurio, F., and Karin, M. (1995) Mol. Cell. Biol. 15, 1302-1311[Abstract] |
| 10. |
Brown, K.,
Gerstberger, S.,
Carlson, L.,
Franzoso, G.,
and Siebenlist, U.
(1995)
Science
267,
1485-1491 |
| 11. |
Chen, Z.,
Hagler, J.,
Palombella, V. J.,
Melandri, F.,
Scherer, D.,
Ballard, D.,
and Maniatis, T.
(1995)
Genes Dev.
9,
1586-1597 |
| 12. | DiDonato, J. A., Mercurio, F., Rosette, C., Wu-li, J., Suyang, H., Ghosh, S., and Karin, M. (1996) Mol. Cell. Biol. 16, 1295-1304[Abstract] |
| 13. | Reach, M., Galindo, R. L., Towb, P., Allen, J. L., Karin, M., and Wasserman, S. A. (1996) Dev. Biol. 180, 353-364[CrossRef][Medline] [Order article via Infotrieve] |
| 14. |
Scherer, D. C.,
Brockman, J.,
Chen, Z.,
Maniatis, T.,
and Ballard, D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
11259-11263 |
| 15. | Hershko, A., and Ciechanover, A. (1998) Annu. Rev. Biochem. 67, 425-479[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Yaron, A., Gonen, H., Alkalay, I., Hatzubai, A., Jung, S., Beyth, S., Mercurio, F., Manning, A. M., Ciechanover, A., and BenNeriah, Y. (1997) EMBO J. 16, 6486-6494[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Yaron, A., Hatzubai, A., Davis, M., Lavon, I., Amit, S., Manning, A. M., Andersen, J. S., Mann, M., Mercurio, F., and Ben-Neriah, Y. (1998) Nature 396, 590-594[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Patton, E. E., Willems, A. R., and Tyers, M. (1998) Trends Genet. 14, 236-243[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J. W., and Elledge, S. J. (1996) Cell 86, 263-274[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Feldman, R. M. R., Correll, C. C., Kaplan, K. B., and Deshaies, R. J. (1997) Cell 91, 221-230[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Skowyra, D., Craig, K. L., Tyers, M., Elledge, S. J., and Harper, J. W. (1997) Cell 91, 209-219[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Margottin, F., Bour, S. P., Durand, H., Selig, L., Benichou, S., Richard, V., Thomas, D., Strebel, K., and Benarous, R. (1998) Mol. Cell 1, 565-574[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997) EMBO J. 16, 3797-3804[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Jiang, J., and Struhl, G. (1998) Nature 391, 493-496[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Winston, J. T.,
Strack, P.,
Beer-Romero, P.,
Chu, C. Y.,
Elledge, S. J.,
and Harper, J. W.
(1999)
Genes Dev.
13,
270-283 |
| 26. | Bender, K., Gottlicher, M., Whiteside, S., Rahmsdorf, H. J., and Herrlich, P. (1998) EMBO J. 17, 5170-5181[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Li, N.,
and Karin, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13012-13017 |
| 28. | Imbert, V., Rupec, R. A., Livolsi, A., Pahl, H. L., Traenckner, E. B., Mueller-Dieckmann, C., Farahifar, D., Rossi, B., Auberger, P., Baeuerle, P. A., and Peyron, J. F. (1996) Cell 86, 787-798[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Beraud, C.,
Henzel, W. J.,
and Baeuerle, P. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
429-434 |
| 30. | DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554[CrossRef][Medline] [Order article via Infotrieve] |
| 31. |
Mercurio, F.,
Zhu, H.,
Murray, B. W.,
Shevchenko, A.,
Bennett, B. L.,
Li, J.,
Young, D. B.,
Barbosa, M.,
Mann, M.,
Manning, A.,
and Rao, A.
(1997)
Science
278,
860-866 |
| 32. | Zandi, E., Rothwarf, D. M., Delhase, M., Hayakawa, M., and Karin, M. (1997) Cell 91, 243-252[CrossRef][Medline] [Order article via Infotrieve] |
| 33. |
Zandi, E.,
Chen, Y.,
and Karin, M.
(1998)
Science
281,
1360-1363 |
| 34. | Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998) Nature 395, 297-300[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. (1998) Cell 93, 1231-1240[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Régnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M. (1997) Cell 90, 373-383[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) Nature 385, 540-544[CrossRef][Medline] [Order article via Infotrieve] |
| 38. |
Woronicz, J. D.,
Gao, X.,
Cao, Z.,
Rothe, M.,
and Goeddel, D. V.
(1997)
Science
278,
866-869 |
| 39. |
Karin, M.,
and Delhase, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
9067-9069 |
| 40. |
Baud, V.,
Liu, Z.-G.,
Bennett, B.,
Suzuki, N.,
Xia, Y.,
and Karin, M.
(1999)
Genes Dev.
13,
1297-1308 |
| 41. | Ling, L., Cao, Z., and Goeddel, D. V. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2791-2797 |
| 42. |
Delhase, M.,
Hayakawa, M.,
Chen, Y.,
and Karin, M.
(1999)
Science
284,
309-313 |
| 43. | Cohen, L., Henzel, W. J., and Baeuerle, P. A. (1998) Nature 395, 292-296[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Zheng, C.-F., and Guan, K.-L. (1994) EMBO J. 13, 1123-1131[Medline] [Order article via Infotrieve] |
| 45. | Johnson, L. N., Noble, M. E. M., and Owen, D. J. (1996) Cell 85, 149-158[CrossRef][Medline] [Order article via Infotrieve] |
| 46. |
Barnes, P. J.,
and Karin, M.
(1997)
N. Engl. J. Med.
336,
1066-1071 |
| 47. | Krappmann, D., Emmerich, F., Kordes, U., Scharschmidt, E., Dorken, B., and Scheidereit, C. (1999) Oncogene 18, 943-953[CrossRef][Medline] [Order article via Infotrieve] |
| 48. | Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C., and Dèorken, B. (1997) J. Clin. Invest. 100, 2961-2969[Medline] [Order article via Infotrieve] |
| 49. | Gilmore, T. D. (1997) J. Clin. Invest. 100, 2935-2936[Medline] [Order article via Infotrieve] |
| 50. |
Hu, Y.,
Baud, V.,
Delhase, M.,
Zhang, P.,
Johnson, R.,
and Karin, M.
(1999)
Science
284,
316-320 |
| 51. |
Li, Q.,
Van Antwerp, D.,
Mercurio, F.,
Lee, K.-F.,
and Verma, I. M.
(1999)
Science
284,
321-325 |
| 52. |
Li, Z. W.,
Chu, W.,
Hu, Y.,
Delhase, M.,
Deerinck, T.,
Ellisman, M.,
Johnson, R.,
and Karin, M.
(1999)
J. Exp. Med.
189,
1839-1845 |
| 53. | Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S., and Baltimore, D. (1995) Nature 376, 167-169[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Horwitz, B. H., Scott, M. L., Cherry, S. R., Bronson, R. T., and Baltimore, D. (1997) Immunity 6, 765-772[CrossRef][Medline] [Order article via Infotrieve] |
| 55. |
Beg, A. A.,
and Baltimore, D.
(1996)
Science
274,
782-784 |
| 56. | Liu, Z.-G., Hu, H., Goeddel, D. V., and Karin, M. (1996) Cell 87, 565-576[CrossRef][Medline] [Order article via Infotrieve] |
| 57. |
Wang, C.-Y.,
Mayo, M. W.,
and Baldwin, A. S., Jr.
(1996)
Science
274,
784-787 |
| 58. |
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789 |
| 59. |
Doi, T. S.,
Marino, M. W.,
Takahashi, T.,
Yoshida, T.,
Sakakura, T.,
Old, L. J.,
and Obata, Y.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2994-2999 |
This article has been cited by other articles:
![]() |
D. Zhang, J. Li, L. Song, W. Ouyang, J. Gao, and C. Huang A JNK1/AP-1-Dependent, COX-2 Induction Is Implicated in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Cell Transformation through Regulating Cell Cycle Progression Mol. Cancer Res., January 1, 2008; 6(1): 165 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ishizuka, J. Cheng, H. Singh, M. D. Vitto, V. L. Manthati, J. R. Falck, and M. Laniado-Schwartzman 20-Hydroxyeicosatetraenoic Acid Stimulates Nuclear Factor-{kappa}B Activation and the Production of Inflammatory Cytokines in Human Endothelial Cells J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 103 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Hwang, C. W. H. Woo, K. K. W. Au-Yeung, Y. L. Siow, T. Y. Zhu, and K. O Homocysteine stimulates monocyte chemoattractant protein-1 expression in the kidney via nuclear factor-{kappa}B activation Am J Physiol Renal Physiol, January 1, 2008; 294(1): F236 - F244. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Shaw, I. A. Eydelnant, and L. A. Kirshenbaum Transgenic Expression of A20 Prevents Cardiac Cell Death and Myocardial Dysfunction After Myocardial Infarction Circulation, April 10, 2007; 115(14): 1827 - 1829. [Full Text] [PDF] |
||||
![]() |
N. G. d. Paz, S. Simeonidis, C. Leo, D. W. Rose, and T. Collins Regulation of NF-{kappa}B-dependent Gene Expression by the POU Domain Transcription Factor Oct-1 J. Biol. Chem., March 16, 2007; 282(11): 8424 - 8434. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Rolland, Z. Madjd, L. Durrant, I. O Ellis, R. Layfield, and I. Spendlove The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease Endocr. Relat. Cancer, March 1, 2007; 14(1): 73 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hnia, G. Hugon, F. Rivier, A. Masmoudi, J. Mercier, and D. Mornet Modulation of p38 Mitogen-Activated Protein Kinase Cascade and Metalloproteinase Activity in Diaphragm Muscle in Response to Free Radical Scavenger Administration in Dystrophin-Deficient Mdx Mice Am. J. Pathol., February 1, 2007; 170(2): 633 - 643. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Rasoulpour and K. Boekelheide NF-kappaB Activation Elicited by Ionizing Radiation Is Proapoptotic in Testis Biol Reprod, February 1, 2007; 76(2): 279 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, H.-J. Tsai, I.-H. Kim, D. Tuteja, R. K. P. Mateo, A. Singapuri, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors PNAS, December 5, 2006; 103(49): 18733 - 18738. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. D. Ramnath and M. Bhatia Subs |